PRLD trades 85.6% below Wall Street's consensus target of $8.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PRLD achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Prelude Therapeutics Incorporated (PRLD) has a Wall Street consensus price target of $8.00, based on estimates from 8 covering analysts. With the stock currently trading at $4.31, this represents a potential upside of +85.6%. The company has a market capitalization of $338M.
Analyst price targets range from a low of $8.00 to a high of $8.00, representing a 0% spread in expectations. The median target of $8.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, PRLD trades at a trailing P/E of -3.3x. Analysts expect EPS to grow +51.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RVMDRevolution Medicines, Inc. | $40.6B | $190.74 | $247.00 | +29.5% | Buy | — | 24 |
 KYMRKymera Therapeutics, Inc. | $9.5B | $115.47 | $136.75 | +18.4% | Buy | — | 27 |
 ARVNArvinas, Inc. | $505M | $7.83 | $14.17 | +81.0% | Buy | — | 26 |
 VKTXViking Therapeutics, Inc. | $4.9B | $41.65 | $91.75 | +120.3% | Buy | — | 24 |
 AUPHAurinia Pharmaceuticals Inc. | $2.1B | $16.40 | $16.00 | -2.4% | Buy | 17.4x | 15 |
 IMVTImmunovant, Inc. | $7.1B | $34.54 | $40.00 | +15.8% | Buy | — | 23 |
 TGTXTG Therapeutics, Inc. | $8.6B | $56.00 | $80.50 | +43.8% | Buy | 55.8x | 13 |
 PTCTPTC Therapeutics, Inc. | $5.2B | $62.34 | $105.13 | +68.6% | Buy | 49.1x | 26 |
 MGNXMacroGenics, Inc. | $242M | $3.80 | $6.00 | +57.9% | Buy | — | 22 |
 PRAXPraxis Precision Medicines, Inc. | $7.9B | $282.12 | $603.83 | +114.0% | Buy | — | 18 |
Quick answers to the most common questions about buying PRLD stock.
The consensus Wall Street price target for PRLD is $8, representing 85.6% upside from the current price of $4.31. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PRLD has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $8 implies 85.6% upside from current levels.
PRLD's current price is $4.31 with a consensus target of $8 (85.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $8 for PRLD, while the most conservative target is $8. The consensus of $8 represents the median expectation. These targets typically reflect 12-month expectations.
PRLD is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PRLD stock forecast based on 8 Wall Street analysts shows a consensus price target of $8, with estimates ranging from $8 (bear case) to $8 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PRLD, with a "Buy" consensus rating and $8 price target (85.6% upside). 5 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PRLD analyst price targets range from $8 to $8, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.